EUVIMEDEUVIMED entdecken
Open Access

Sotagliflozin, a Dual SGLT1/2 Inhibitor, Modulates DNMT1 and Class I/II HDAC Expression in Association With Anticancer Effects in Breast and Lung Cancer Cells

P K Hima iD, K Aswathy iD, Govinda Rao Duddukuri iD

Cell Biology International · 2026-09 · 50 (9)

DOI: 10.1002/cbin.70201 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Biology International, online erschienen am 01.09.2026. Verfasst von P K Hima und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology, School of Biological Sciences, Central University of Kerala, Kasaragod, Kerala, India. Hauptthemen laut MEDLINE: DNA (Cytosine-5-)-Methyltransferase 1, Lung Neoplasms, Sodium-Glucose Transporter 1, Breast Neoplasms. Die Arbeit nennt 72 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Council of Scientific and Industrial Research-University Grants Commission (CSIR-UGC), India, Junior Research Fellowship (JRF) from the Kerala State Council for Science, Technology, and Environment (KSCSTE), Kerala, India.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sodium–glucose cotransporter (SGLT) inhibitors are increasingly recognised for anticancer activity beyond their established glycaemic effects. While selective SGLT2 inhibitors have been reported to suppress tumour cell proliferation and modulate AMPK/mTOR and PI3K/AKT signalling, whether dual SGLT1/2 inhibition is associated with modulation of epigenetic regulators has remained largely unexplored. Here, we investigated the anticancer effects of sotagliflozin, a dual SGLT1/2 inhibitor, in breast (MCF‐7) and lung (A549) cancer cells. Sotagliflozin reduced cell viability, clonogenic survival, migration, and invasion, and these effects were accompanied by G2/M cell‐cycle arrest, increased AMPK activation, and changes in PTEN–AKT–mTOR signalling. Molecular docking analysis predicted favourable interactions between sotagliflozin and DNA methyltransferases (DNMT1, DNMT3A, and DNMT3B), with the strongest predicted binding to DNMT1 (−8.9 kcal/mol). Consistent with these computational predictions, sotagliflozin treatment was associated with reduced total DNMT enzymatic activity, decreased DNMT1 mRNA and protein abundance, and reduced protein abundance of class I and class II histone deacetylases (HDAC1–4 and HDAC6) in both cell lines. In addition, sotagliflozin treatment was associated with autophagy‐related changes, including increased acidic vesicular organelles together with elevated LC3‐II and Beclin‐1 protein abundance. Collectively, these findings demonstrate that sotagliflozin exerts broad anticancer effects in breast and lung cancer cells and provide preliminary evidence that its treatment is associated with modulation of DNMT1 and HDAC expression. Further studies are required to determine whether these epigenetic changes contribute directly to the observed cellular responses or represent downstream consequences of metabolic perturbation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DNA (Cytosine-5-)-Methyltransferase 1Lung NeoplasmsSodium-Glucose Transporter 1Breast NeoplasmsSodium-Glucose Transporter 2 InhibitorsAntineoplastic AgentsHistone DeacetylasesGlycosidesHumansFemaleMCF-7 CellsMolecular Docking SimulationCell ProliferationCell SurvivalCell Line, TumorA549 CellsCell MovementSignal TransductionDNA (Cytosine-5-)-MethyltransferasesHistone Deacetylase 2

Stichwörter der Autor:innen

DNMT1HDACSGLT1/2 inhibitoranticancer activitybreast cancerepigeneticslung cancersotagliflozin

Substanzen

DNA (Cytosine-5-)-Methyltransferase 1Sodium-Glucose Transporter 1DNMT1 protein, humanSodium-Glucose Transporter 2 InhibitorsAntineoplastic AgentsHistone DeacetylasesDNA (Cytosine-5-)-MethyltransferasesGlycosidesSLC5A1 protein, humanHistone Deacetylase 2

Autor:innen und Institutionen

  • Department of Biochemistry and Molecular Biology, School of Biological Sciences, Central University of Kerala, Kasaragod, Kerala, India.

ORCID-Profile: P K Hima, K Aswathy, Govinda Rao Duddukuri

Förderung

  • Council of Scientific and Industrial Research-University Grants Commission (CSIR-UGC), India
  • Junior Research Fellowship (JRF) from the Kerala State Council for Science, Technology, and Environment (KSCSTE), Kerala, India

Zitieren

APA

Hima, P. K., Aswathy, K., & Duddukuri, G. R. (2026). Sotagliflozin, a Dual SGLT1/2 Inhibitor, Modulates DNMT1 and Class I/II HDAC Expression in Association With Anticancer Effects in Breast and Lung Cancer Cells. Cell Biology International, 50(9). https://doi.org/10.1002/cbin.70201

Vancouver

Hima PK, Aswathy K, Duddukuri GR. Sotagliflozin, a Dual SGLT1/2 Inhibitor, Modulates DNMT1 and Class I/II HDAC Expression in Association With Anticancer Effects in Breast and Lung Cancer Cells. Cell Biology International. 2026;50(9). doi:10.1002/cbin.70201

BibTeX
@article{Hima2026,
  author = {Hima, P K and Aswathy, K and Duddukuri, Govinda Rao},
  title = {Sotagliflozin, a Dual SGLT1/2 Inhibitor, Modulates DNMT1 and Class I/II HDAC Expression in Association With Anticancer Effects in Breast and Lung Cancer Cells},
  journal = {Cell Biology International},
  year = {2026},
  volume = {50},
  number = {9},
  doi = {10.1002/cbin.70201}
}
Kostenlos starten →